Stevanato Group (NYSE:STVN) vs. Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Critical Review

Stevanato Group (NYSE:STVN) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations for Stevanato Group and Health Sciences Acquisitions Co. 2, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0	1	5	0	2.83
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00

Volatility and Risk

Stevanato Group has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stevanato Group and Health Sciences Acquisitions Co. 2″s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.17 billion	N/A	$157.62 million	€0.47 ($0.49)	49.60
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A

Stevanato Group has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Profitability

This table compares Stevanato Group and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.47%	9.86%	5.79%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Institutional & Insider Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Stevanato Group beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.